GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advagene Biopharma Co Ltd (ROCO:6709) » Definitions » EV-to-Revenue

Advagene Biopharma Co (ROCO:6709) EV-to-Revenue : (As of Jun. 23, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Advagene Biopharma Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Advagene Biopharma Co's enterprise value is NT$1,135.45 Mil. Advagene Biopharma Co's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was NT$0.00 Mil. Therefore, Advagene Biopharma Co's EV-to-Revenue for today is .

The historical rank and industry rank for Advagene Biopharma Co's EV-to-Revenue or its related term are showing as below:

ROCO:6709's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.69
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-23), Advagene Biopharma Co's stock price is NT$23.60. Advagene Biopharma Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was NT$0.00. Therefore, Advagene Biopharma Co's PS Ratio for today is .


Advagene Biopharma Co EV-to-Revenue Historical Data

The historical data trend for Advagene Biopharma Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advagene Biopharma Co EV-to-Revenue Chart

Advagene Biopharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial - - - - -

Advagene Biopharma Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Advagene Biopharma Co's EV-to-Revenue

For the Biotechnology subindustry, Advagene Biopharma Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advagene Biopharma Co's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advagene Biopharma Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Advagene Biopharma Co's EV-to-Revenue falls into.



Advagene Biopharma Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Advagene Biopharma Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1135.447/0
=

Advagene Biopharma Co's current Enterprise Value is NT$1,135.45 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Advagene Biopharma Co's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was NT$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advagene Biopharma Co  (ROCO:6709) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Advagene Biopharma Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=23.60/0
=

Advagene Biopharma Co's share price for today is NT$23.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2023 was NT$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advagene Biopharma Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Advagene Biopharma Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Advagene Biopharma Co (ROCO:6709) Business Description

Traded in Other Exchanges
N/A
Address
Sector 1, Neihu Road, 6 Floor, No.308, Neihu District, Taipei, TWN, 114
Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based drug developer. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray influenza vaccine (LT-Flu), allergy vaccines (LT-Allergy), and other vaccines.

Advagene Biopharma Co (ROCO:6709) Headlines

No Headlines